Reference is made to the offer document dated 11 September 2017 regarding Karo Pharma AB's ("Karo Pharma") conditional voluntary offer (the "Voluntary Offer") to acquire all of the shares in Weifa ASA ("Weifa") at NOK 35 per share. As of today Karo Pharma has received acceptances under the Voluntary Offer for a total of 32 949 919 shares representing approximately 90.3 % of the total shares in Weifa on a fully diluted basis. This includes the shares comprised by pre-acceptances. Accordingly, the conditions for completion of the Voluntary Offer have now been met.
The offer period for the Voluntary Offer expires at 16:30 hours CEST on 3 October 2017. The offer period will not be extended any further by Karo Pharma.
Shareholders who have yet to accept the Voluntary Offer may complete and sign an acceptance form and return it prior to the expiry of the offer period to:
DNB Markets E-mail: retail@dnb.no Tel: +47 23 26 81 01
The offer document and the acceptance form are available at www.dnb.no/emisjoner .
Following settlement of the Voluntary Offer, Karo Pharma intends to initiate a compulsory acquisition of the remaining outstanding shares of Weifa in accordance with applicable laws, and to propose that Weifa applies for a delisting of its shares from Oslo Børs.
